300584 海辰药业
已收盘 12-24 15:00:00
资讯
新帖
简况
海辰药业(300584)12月24日主力资金净卖出485.32万元
证券之星 · 15:32
海辰药业(300584)12月24日主力资金净卖出485.32万元
海辰药业(300584)12月10日股东户数1.41万户,较上期减少21.88%
证券之星 · 12-19
海辰药业(300584)12月10日股东户数1.41万户,较上期减少21.88%
海辰药业(300584)股东曹于平质押400万股,占总股本3.33%
证券之星 · 12-03
海辰药业(300584)股东曹于平质押400万股,占总股本3.33%
海辰药业(300584)11月27日主力资金净卖出854.21万元
证券之星 · 11-27
海辰药业(300584)11月27日主力资金净卖出854.21万元
海辰药业(300584)11月22日主力资金净卖出249.96万元
证券之星 · 11-22
海辰药业(300584)11月22日主力资金净卖出249.96万元
海辰药业最新公告:注射用盐酸兰地洛尔增加150mg规格获得药品补充申请批准通知书
证券之星 · 11-06
海辰药业最新公告:注射用盐酸兰地洛尔增加150mg规格获得药品补充申请批准通知书
海辰药业最新公告:伏格列波糖片通过仿制药质量和疗效一致性评价
证券之星 · 10-28
海辰药业最新公告:伏格列波糖片通过仿制药质量和疗效一致性评价
海辰药业(300584.SZ):伏格列波糖片通过一致性评价
智通财经 · 10-28
海辰药业(300584.SZ):伏格列波糖片通过一致性评价
海辰药业(300584)2024年三季报简析:净利润增25.4%,盈利能力上升
证券之星 · 10-27
海辰药业(300584)2024年三季报简析:净利润增25.4%,盈利能力上升
图解海辰药业三季报:第三季度单季净利润同比增14.69%
证券之星 · 10-25
图解海辰药业三季报:第三季度单季净利润同比增14.69%
海辰药业(300584)9月30日股东户数1.7万户,较上期减少5.88%
证券之星 · 10-25
海辰药业(300584)9月30日股东户数1.7万户,较上期减少5.88%
海辰药业(300584.SZ)发布前三季度业绩,净利润2811.68万元,同比增长25.4%
智通财经 · 10-25
海辰药业(300584.SZ)发布前三季度业绩,净利润2811.68万元,同比增长25.4%
海辰药业(300584)10月25日主力资金净卖出1780.28万元
证券之星 · 10-25
海辰药业(300584)10月25日主力资金净卖出1780.28万元
A股化学制药板块强势拉升,科源制药20cm涨停,无锡晶海涨超10%,川宁生物、尔康制药、振东制药赛托生物、海辰药业等跟涨。
美港电讯 · 10-24
A股化学制药板块强势拉升,科源制药20cm涨停,无锡晶海涨超10%,川宁生物、尔康制药、振东制药赛托生物、海辰药业等跟涨。
海辰药业(300584.SZ)拟对安庆汇辰增资2亿元并为其引入1.25亿元新投资
智通财经网 · 10-11
海辰药业(300584.SZ)拟对安庆汇辰增资2亿元并为其引入1.25亿元新投资
海辰药业(300584)9月20日股东户数1.8万户,较上期增加25.32%
证券之星 · 09-23
海辰药业(300584)9月20日股东户数1.8万户,较上期增加25.32%
A股创新药板块持续反弹,百济神州涨超6%,股价创年内新高,贝达药业、荣昌生物涨超7%,皓元医药、百利天恒、海辰药业、神州细胞、上海谊众等涨幅靠前。
美港电讯 · 09-11
A股创新药板块持续反弹,百济神州涨超6%,股价创年内新高,贝达药业、荣昌生物涨超7%,皓元医药、百利天恒、海辰药业、神州细胞、上海谊众等涨幅靠前。
海辰药业(300584)9月2日主力资金净卖出360.50万元
证券之星 · 09-02
海辰药业(300584)9月2日主力资金净卖出360.50万元
A股医药股震荡走低,兴齐眼药跌超15%,普利制药跌逾10%,金石亚药、海辰药业、亚太药业、同和药业等跌幅居前。
美港电讯 · 08-29
A股医药股震荡走低,兴齐眼药跌超15%,普利制药跌逾10%,金石亚药、海辰药业、亚太药业、同和药业等跌幅居前。
8月27日海辰药业(300584)龙虎榜数据:游资量化打板上榜
证券之星 · 08-27
8月27日海辰药业(300584)龙虎榜数据:游资量化打板上榜
加载更多
公司概况
公司名称:
南京海辰药业股份有限公司
所属行业:
医药制造业
上市日期:
2017-01-12
主营业务:
南京海辰药业股份有限公司的主营业务为化学制剂、原料药及中间体的研发、生产、销售。公司主要产品为注射用托拉塞米,注射用替加环素,注射用盐酸兰地洛尔,注射用头孢西酮钠,注射用头孢替安,利伐沙班片,恩替卡韦片等。研发中心承担“国家重点产业振兴与技术改造项目”、“国家火炬计划项目”、“江苏省科技成果转化项目”等国家及省市级科技项目20余项,是江苏省认定的“省免疫调节药物工程技术中心”、“省企业技术中心”。随着一系列研发技术平台的建设,为高技术壁垒的高端仿制药和创新药研发奠定了基础,为公司持续发展带来了有力驱动。
发行价格:
11.11
{"stockData":{"symbol":"300584","market":"SZ","secType":"STK","nameCN":"海辰药业","latestPrice":20.77,"timestamp":1735023795000,"preClose":21.31,"halted":0,"volume":2735358,"delay":0,"floatShares":82118600,"shares":120000000,"eps":0.3501,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.54,"latestTime":"12-24 15:00:00","open":21.52,"high":21.52,"low":20.38,"amount":57013700,"amplitude":0.0535,"askPrice":20.77,"askSize":55,"bidPrice":20.75,"bidSize":65,"shortable":0,"etf":0,"ttmEps":0.3501,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735090200000},"adr":0,"adjPreClose":21.31,"symbolType":"stock","openAndCloseTimeList":[[1735003800000,1735011000000],[1735016400000,1735023600000]],"highLimit":23.44,"lowLimit":19.18,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":120000000,"pbRate":2.53,"roa":"--","roe":"2.81%","epsLYR":0.3026,"committee":0.331476,"marketValue":2492000000,"floatMarketCap":1706000000,"peRate":59.325905,"changeRate":-0.0253,"turnoverRate":0.0333,"status":1},"requestUrl":"/m/hq/s/300584","defaultTab":"news","newsList":[{"id":"2493779847","title":"海辰药业(300584)12月24日主力资金净卖出485.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493779847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493779847?lang=zh_cn&edition=full","pubTime":"2024-12-24 15:32","pubTimestamp":1735025569,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年12月24日收盘,海辰药业报收于20.77元,下跌2.53%,换手率3.33%,成交量2.74万手,成交额5701.37万元。12月24日的资金流向数据方面,主力资金净流出485.32万元,占总成交额8.51%,游资资金净流出79.14万元,占总成交额1.39%,散户资金净流入564.47万元,占总成交额9.9%。海辰药业主营业务:化学制剂、原料药及中间体的研发、生产、销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122400022879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2492149496","title":"海辰药业(300584)12月10日股东户数1.41万户,较上期减少21.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492149496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492149496?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:11","pubTimestamp":1734599465,"startTime":"0","endTime":"0","summary":"证券之星消息,近日海辰药业披露,截至2024年12月10日公司股东户数为1.41万户,较10月18日减少3945.0户,减幅为21.88%。在化学制药行业个股中,海辰药业股东户数低于行业平均水平,截至12月10日,化学制药行业平均股东户数为3.11万户。从股价来看,2024年10月18日至2024年12月10日,海辰药业区间涨幅为0.63%,在此期间股东户数减少3945.0户,减幅为21.88%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900028352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2488910501","title":"海辰药业(300584)股东曹于平质押400万股,占总股本3.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488910501","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488910501?lang=zh_cn&edition=full","pubTime":"2024-12-03 21:37","pubTimestamp":1733233031,"startTime":"0","endTime":"0","summary":"证券之星消息,海辰药业12月3日公开信息显示,股东曹于平向中国银河证券股份有限公司合计质押400.0万股,占总股本3.33%。质押详情见下表:截止本公告日,股东曹于平已累计质押股份400.0万股,占其持股总数的7.92%。海辰药业主营业务:化学制剂、原料药及中间体的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120300039317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2486811433","title":"海辰药业(300584)11月27日主力资金净卖出854.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486811433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486811433?lang=zh_cn&edition=full","pubTime":"2024-11-27 15:31","pubTimestamp":1732692697,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月27日收盘,海辰药业报收于22.23元,下跌0.8%,换手率4.92%,成交量4.04万手,成交额8821.29万元。11月27日的资金流向数据方面,主力资金净流出854.21万元,占总成交额9.68%,游资资金净流入235.33万元,占总成交额2.67%,散户资金净流入618.88万元,占总成交额7.02%。海辰药业主营业务:化学制剂、原料药及中间体的研发、生产、销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112700020183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2485822872","title":"海辰药业(300584)11月22日主力资金净卖出249.96万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485822872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485822872?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:32","pubTimestamp":1732260739,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月22日收盘,海辰药业报收于22.27元,下跌6.55%,换手率6.31%,成交量5.18万手,成交额1.19亿元。11月22日的资金流向数据方面,主力资金净流出249.96万元,占总成交额2.1%,游资资金净流出326.58万元,占总成交额2.74%,散户资金净流入576.54万元,占总成交额4.84%。海辰药业主营业务:化学制剂、原料药及中间体的研发、生产、销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200020151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2481415625","title":"海辰药业最新公告:注射用盐酸兰地洛尔增加150mg规格获得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481415625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481415625?lang=zh_cn&edition=full","pubTime":"2024-11-06 16:16","pubTimestamp":1730881013,"startTime":"0","endTime":"0","summary":"海辰药业公告称,公司收到国家药监局核准签发的注射用盐酸兰地洛尔的《药品补充申请批准通知书》,同意在已批准规格50mg基础上增加规格150mg,且视同通过一致性评价。注射用盐酸兰地洛尔是一种新型的超短效肾上腺素β受体阻滞药,主要用于手术过程中及手术后循环系统动态监护时发生的快速性心律失常的紧急治疗。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600026969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300584"],"gpt_icon":0},{"id":"2478109932","title":"海辰药业最新公告:伏格列波糖片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2478109932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478109932?lang=zh_cn&edition=full","pubTime":"2024-10-28 19:30","pubTimestamp":1730115033,"startTime":"0","endTime":"0","summary":"海辰药业公告,公司于近日收到国家药品监督管理局核准签发的《药品补充申请批准通知书》,伏格列波糖片通过仿制药质量和疗效一致性评价。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800027406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2478127986","title":"海辰药业(300584.SZ):伏格列波糖片通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2478127986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478127986?lang=zh_cn&edition=full","pubTime":"2024-10-28 15:46","pubTimestamp":1730101591,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海辰药业(300584.SZ)公告,公司近日收到国家药品监督管理局核准签发的《药品补充申请批准通知书》,伏格列波糖片通过仿制药质量和疗效一致性评价。伏格列波糖片为口服类降糖药,属于α-葡萄糖苷酶抑制剂,在肠道内抑制将双糖分解成单糖的α-葡萄糖苷酶,从而延迟糖分的消化和吸收,改善餐后高血糖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2478012181","title":"海辰药业(300584)2024年三季报简析:净利润增25.4%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2478012181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478012181?lang=zh_cn&edition=full","pubTime":"2024-10-27 10:59","pubTimestamp":1729997984,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期海辰药业发布2024年三季报。截至本报告期末,公司营业总收入3.6亿元,同比下降4.62%,归母净利润2811.68万元,同比上升25.4%。按单季度数据看,第三季度营业总收入1.24亿元,同比上升6.5%,第三季度归母净利润338.05万元,同比上升14.69%。本报告期海辰药业盈利能力上升,毛利率同比增幅12.06%,净利率同比增幅26.08%。去年的净利率为7.01%,算上全部成本后,公司产品或服务的附加值一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700011386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584"],"gpt_icon":0},{"id":"2478606890","title":"图解海辰药业三季报:第三季度单季净利润同比增14.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478606890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478606890?lang=zh_cn&edition=full","pubTime":"2024-10-25 17:29","pubTimestamp":1729848593,"startTime":"0","endTime":"0","summary":"证券之星消息,海辰药业2024年三季报显示,公司主营收入3.6亿元,同比下降4.62%;归母净利润2811.68万元,同比上升25.4%;扣非净利润2906.63万元,同比上升35.4%;其中2024年第三季度,公司单季度主营收入1.24亿元,同比上升6.5%;单季度归母净利润338.05万元,同比上升14.69%;单季度扣非净利润355.09万元,同比上升37.32%;负债率29.02%,投资收益-12.04万元,财务费用685.4万元,毛利率83.1%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500031113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584"],"gpt_icon":0},{"id":"2478360313","title":"海辰药业(300584)9月30日股东户数1.7万户,较上期减少5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478360313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478360313?lang=zh_cn&edition=full","pubTime":"2024-10-25 17:11","pubTimestamp":1729847518,"startTime":"0","endTime":"0","summary":"证券之星消息,近日海辰药业披露,截至2024年9月30日公司股东户数为1.7万户,较9月20日减少1060.0户,减幅为5.88%。在化学制药行业个股中,海辰药业股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.13万户。从股价来看,2024年9月20日至2024年9月30日,海辰药业区间涨幅为28.23%,在此期间股东户数减少1060.0户,减幅为5.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500030256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300584"],"gpt_icon":0},{"id":"2478773276","title":"海辰药业(300584.SZ)发布前三季度业绩,净利润2811.68万元,同比增长25.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478773276","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478773276?lang=zh_cn&edition=full","pubTime":"2024-10-25 16:23","pubTimestamp":1729844632,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海辰药业(300584.SZ)发布2024年第三季度报告,公司前三季度营业收入3.6亿元,同比下降4.62%;归属于上市公司股东的净利润2811.68万元,同比增长25.40%;归属于上市公司股东的扣除非经常性损益的净利润2906.63万元,同比增长35.40%;基本每股收益0.2343元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300584"],"gpt_icon":0},{"id":"2478362676","title":"海辰药业(300584)10月25日主力资金净卖出1780.28万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478362676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478362676?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:21","pubTimestamp":1729840867,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月25日收盘,海辰药业报收于23.06元,下跌1.45%,换手率9.77%,成交量8.03万手,成交额1.83亿元。10月25日的资金流向数据方面,主力资金净流出1780.28万元,占总成交额9.73%,游资资金净流入234.01万元,占总成交额1.28%,散户资金净流入1546.27万元,占总成交额8.45%。海辰药业主营业务:化学制剂、原料药及中间体的研发、生产、销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500020069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2477651489","title":"A股化学制药板块强势拉升,科源制药20cm涨停,无锡晶海涨超10%,川宁生物、尔康制药、振东制药赛托生物、海辰药业等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2477651489","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477651489?lang=zh_cn&edition=full","pubTime":"2024-10-24 09:32","pubTimestamp":1729733526,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["301281","300584","399300","300267","01477","BK0239","BK1574","300158","BK0028","BK1191","BK0186","301301","300583","BK0060","159982","BK0077"],"gpt_icon":0},{"id":"2474051033","title":"海辰药业(300584.SZ)拟对安庆汇辰增资2亿元并为其引入1.25亿元新投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2474051033","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474051033?lang=zh_cn&edition=full","pubTime":"2024-10-11 15:58","pubTimestamp":1728633507,"startTime":"0","endTime":"0","summary":"海辰药业(300584.SZ)公告,公司全资子公司安庆汇辰科技有限公司(“安庆汇辰...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1192795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2469160799","title":"海辰药业(300584)9月20日股东户数1.8万户,较上期增加25.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2469160799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469160799?lang=zh_cn&edition=full","pubTime":"2024-09-23 17:06","pubTimestamp":1727082360,"startTime":"0","endTime":"0","summary":"证券之星消息,近日海辰药业披露,截至2024年9月20日公司股东户数为1.8万户,较8月9日增加3643.0户,增幅为25.32%。在化学制药行业个股中,海辰药业股东户数低于行业平均水平,截至9月20日,化学制药行业平均股东户数为3.2万户。从股价来看,2024年8月9日至2024年9月20日,海辰药业区间涨幅为7.61%,在此期间股东户数增加3643.0户,增幅为25.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092300020131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300584"],"gpt_icon":0},{"id":"2466429071","title":"A股创新药板块持续反弹,百济神州涨超6%,股价创年内新高,贝达药业、荣昌生物涨超7%,皓元医药、百利天恒、海辰药业、神州细胞、上海谊众等涨幅靠前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2466429071","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466429071?lang=zh_cn&edition=full","pubTime":"2024-09-11 13:29","pubTimestamp":1726032558,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1064131003.USD","BK0216","159992","LU0307460666.USD","LU1969619763.USD","BK4548","688506","688520","159982","300584","09995","LU0588546209.SGD","399300","BK4505","BK0060","BK1161","06160","300558","BK4504","BK4585","BK1574","LU2148510915.USD","BGNE","LU1064130708.USD","688331","BK0239","BK4535","BK4139","688091","LU2328871848.SGD","BK4526","BK4588","BK1583","688131","BK1588","06978","688235","BK1500"],"gpt_icon":0},{"id":"2464001147","title":"海辰药业(300584)9月2日主力资金净卖出360.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464001147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464001147?lang=zh_cn&edition=full","pubTime":"2024-09-02 15:19","pubTimestamp":1725261599,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月2日收盘,海辰药业报收于23.32元,上涨1.75%,换手率21.26%,成交量17.46万手,成交额4.13亿元。9月2日的资金流向数据方面,主力资金净流出360.5万元,占总成交额0.87%,游资资金净流出225.66万元,占总成交额0.55%,散户资金净流入586.15万元,占总成交额1.42%。海辰药业主营业务:化学制剂、原料药及中间体的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090200013191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0},{"id":"2463425223","title":"A股医药股震荡走低,兴齐眼药跌超15%,普利制药跌逾10%,金石亚药、海辰药业、亚太药业、同和药业等跌幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2463425223","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463425223?lang=zh_cn&edition=full","pubTime":"2024-08-29 09:41","pubTimestamp":1724895668,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09939","300434","300630","BK0028","BK0077","159982","BK1161","BK1515","300636","300584","BK1574","BK0177","BK0132","BK0239","399300","300573","159938","002370"],"gpt_icon":0},{"id":"2462156928","title":"8月27日海辰药业(300584)龙虎榜数据:游资量化打板上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2462156928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462156928?lang=zh_cn&edition=full","pubTime":"2024-08-27 17:24","pubTimestamp":1724750689,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2024年8月27日公布的交易公开信息显示,海辰药业因日涨幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2024年8月27日收盘,海辰药业报收于23.26元,上涨20.02%,涨停,换手率15.73%,成交量12.92万手,成交额2.86亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入821.31万元。量化打板等知名游资榜上有名。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082700030244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300584","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-01-12","address":"江苏省南京市栖霞区经济技术开发区恒发路1号","stockEarnings":[{"period":"1week","weight":-0.0694},{"period":"1month","weight":-0.0431},{"period":"3month","weight":0.1575},{"period":"6month","weight":0.3748},{"period":"1year","weight":-0.0761},{"period":"ytd","weight":-0.0817}],"companyName":"南京海辰药业股份有限公司","boardCode":"AI0027","perCapita":"5829股","boardName":"医药制造业","registeredCapital":"12000万元","compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1705},{"period":"6month","weight":0.1274},{"period":"1year","weight":0.1497},{"period":"ytd","weight":0.1265}],"survey":" 南京海辰药业股份有限公司的主营业务为化学制剂、原料药及中间体的研发、生产、销售。公司主要产品为注射用托拉塞米,注射用替加环素,注射用盐酸兰地洛尔,注射用头孢西酮钠,注射用头孢替安,利伐沙班片,恩替卡韦片等。研发中心承担“国家重点产业振兴与技术改造项目”、“国家火炬计划项目”、“江苏省科技成果转化项目”等国家及省市级科技项目20余项,是江苏省认定的“省免疫调节药物工程技术中心”、“省企业技术中心”。随着一系列研发技术平台的建设,为高技术壁垒的高端仿制药和创新药研发奠定了基础,为公司持续发展带来了有力驱动。","serverTime":1735051752707,"listedPrice":11.11,"stockholders":"14087人(较上一季度减少17.00%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海辰药业(300584)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海辰药业(300584)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海辰药业,300584,海辰药业股票,海辰药业股票老虎,海辰药业股票老虎国际,海辰药业行情,海辰药业股票行情,海辰药业股价,海辰药业股市,海辰药业股票价格,海辰药业股票交易,海辰药业股票购买,海辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海辰药业(300584)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海辰药业(300584)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}